Categories
News on Health & Science

Antidepressants and Other Psychotropic Medications Linked to Birth Defects

[amazon_link asins=’B01ETQXMM8,074326973X,B017IFYFW8,B001RJ9AFY,B01MYBLTFD,B00OBTY4BC,B01D9OU5J4,B06XD4CLTY,B00AV5NQH8′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’9587e8d5-053f-11e7-946e-6b9cc5483b07′][amazon_link asins=’B00CRWJI2A’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’6f269f45-053f-11e7-a399-abb68517b491′]

 

Between 1998 and 2007, psychotropic medications were associated with 429 adverse drug reactions in Danish children under the age of 17. More than half of the 429 cases were serious and several involved birth defects, such as birth deformities and severe withdrawal syndromes.
CLICK & SEE
Professors Lise Aagaard and Ebbe Holme Hansen studied all 4,500 pediatric adverse drug reaction reports submitted during the study period to find those which were linked to psychotropic medications. The two researchers found that 42 percent of adverse reactions were reported for psychostimulants, such as Ritalin, which treats attention deficit disorder (ADD), followed by 31 percent for antidepressants, such as Prozac, and 24 percent for antipsychotics, such as Haldol.

“A range of serious side effects such as birth deformities, low birth weight, premature birth, and development of neonatal withdrawal syndrome were reported in children under two years of age, most likely because of the mother’s intake of psychotropic medication during pregnancy,” says Associate Professor Lisa Aagaard.

The researchers believe that these tendencies should serve as a warning to doctors and health care personnel.

“Psychotropic medication should not be prescribed in ordinary circumstances, because this type of medication has a long half-life. If people take their medicine as prescribed it will be a constantly high dosage, and it could take weeks for one single tablet to exit the body’s system. Three out of four pregnancies are planned, and therefore society must take responsibility for informing women about the serious risks of transferring side effects to their unborn child,” says Aagaard.

There is a clear indication that use of antidepressants is increasing in Denmark, as well as in many other countries, and the tendency is the same when it comes to pregnant women.

“We are constantly reminded about the dangers of alcohol use and smoking during pregnancy, but there is no information offered to women with regards to use of psychotropic medication. There is simply not enough knowledge available in this area,” concludes Aagaard, suggesting that greater control should be required when prescribing psychotropic medications to pregnant women.


Source:
Elements4Health:25 June 2010

Enhanced by Zemanta
Categories
Herbs & Plants

Trumpet Creeper (Campsis grandiflora)

[amazon_link asins=’B00Q6Y322W,B01MR88A5X’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’60b1f65c-2836-11e7-b1eb-b3e4a8cfebae’]

Botanical Name : Campsis grandiflora
Family : Bignoniaceae
Genus : Campsis
Kingdom: Plantae
Order: Lamiales
Species: C. grandiflora

Synonyms : Bignonia chinensis – Lam.,Bignonia grandiflora – Thunb.,Campsis adrepens – Lour.,Campsis chinensis – Voss.,Tecoma grandiflora – (Thunb.)Loisel.
Common Name : Chinese Trumpet Vine
Habitat :   A native of East Asia, China and Japan  . Climbs into trees and grows on rocks.
Woodland Garden; Ground Cover;

Description:
It is a fast growing, deciduous creeper with large, orange, trumpet-shaped flowers in summer. It can grow to a height of 9 meters. It is less hardy than its relative Campsis  radicans.The dark green leaves have serrated edges.Chinese trumpet  creeper is a showcase drop-dead,absolutely gorgeous vine, the perfectplant for that special full sun spot. Positioned so the backdrop is a dark  evergreen, the plant literally erupts  into a carpet of three-inch reddishorange  flowers tinged with yellow and salmon hues. On a post, this bright  petunia-on-a-stick will shock and awe  the most jaded of gardeners. At the  SFA Mast Arboretum, flowering rolls in  on a surge in early summer. The show lasts a month, and then the vine  casually throws a few flowers off and  on for the rest of the year, depending  on plant health.

CLICK & SEE THE PICTURES.

Leaves are decidious, 8-12 in (20-30 cm) long, serrated, green to dark-green, pinnate, with 7-9 lanceolate and oval leaflets.
Flowers appear in summer. They are trumpet shaped, orange or red and grouped in terminal clusters of 6-12 flowers. Each flower is about 4-6 in (10-15 cm) long.
Fruits are flattened pods that contain numerous winged seeds.

Campsis grandiflora prefers well drained sandy soil and a position with full sun and support to climb. The dark green leaves have serrated edges.

It is hardy to zone 7 and is frost tender. It is in leaf from June to October, in flower from August to September. The flowers are hermaphrodite (have both male and female organs)
The plant prefers light (sandy), medium (loamy) and heavy (clay) soils and requires well-drained soil. The plant prefers acid, neutral and basic (alkaline) soils. It cannot grow in the shade. It requires moist soil. The plant can tolerate maritime exposure.

Cultivation :
Succeeds in a good well-drained loam and a very sunny position  or light shade. Tolerates moderately alkaline or moderately acid soils.  Dormant plants are hardy to about -10°c, though they require a sunny sheltered wall or hot summers if they are to flower well. The fresh young growth in spring is often damaged by late frosts. Plants can take some years to settle down before they start to flower. They climb by means of aerial roots but need to be supported. Another report says that this species does not produce aerial roots. Plants can be pruned like grapes (Vitis spp.) and any pruning is best done in the spring.  The sub-species C. grandiflora thunbergii tolerates saline winds. Hybridizes freely with other members of this genus.

Propagation:
Seed – sow spring in a greenhouse at 10°c. Two months stratification at 5°c assists germination. When they are large enough to handle, prick the seedlings out into individual pots and grow them on in a greenhouse for at least their first winter. Plant them out into their permanent positions in late spring or early summer, after the last expected frosts. Cuttings of almost ripe wood, 7 – 10cm long, July/August in a frame. Slow to root but a fair percentage. Root cuttings 5cm long in December. Fair to good percentage. Division of suckers in the dormant season. Layering in winter. Plants often self-layer

Medicinal  Actions & Uses
Blood tonic; Carminative; Diuretic; Febrifuge; Women’s complaints.

The flowers and the whole plant are blood tonic, carminative, depurative diuretic and febrifuge. They are used in the treatment of women’s complaints. A decoction of the flowers is used to correct menstrual disorders, rheumatoid pains, traumatic injuries, difficult urination, pruritis and oozing dermaphytoses.

Other Uses:
Ground cover.

Plants can be allowed to scramble on the ground and will form an effective ground cover, rooting at intervals along the branches. They should be planted about 2.5 metres apart each way.

Disclaimer:The information presented herein is intended for educational purposes only. Individual results may vary, and before using any supplements, it is always advisable to consult with your own health care provider

Resources:
http://www.pfaf.org/database/plants.php?Campsis+grandiflora
http://en.wikipedia.org/wiki/Campsis_grandiflora

Click to access Campsis%20grandiflora.pdf

http://coolexotics.com/plant-521-campsis-grandiflora.html
http://commons.wikimedia.org/wiki/Campsis_grandiflora

Reblog this post [with Zemanta]
Categories
Herbs & Plants

Baphicacanthus cusia

[amazon_link asins=’B00NPOI13Q,B01BKIBVCG,B012AZY31Y,B003IIN7HO,B009MP7DEA,B00MGUN86A,B009YSTOE2,B0722H2596,B01IPA7PUY’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’c4fd699c-8af2-11e7-8c40-71629ee30008′]

Botanical Name :Baphicacanthus cusia
Family : Acanthaceae
Genus: Baphicacanthus
Synonyms: Strobilanthes cusia – (Nees.)Kuntze.,Strobilanthes flaccidifolius – Nees.


Other Names:
Natural Indigo , Indigo Naturalis, Baphicacanthus cusia (Nees) Bremek. Polygonum tinctorium Ait. ,Isatis indigotica Fort. Extract

Habitat: E. Asia – China, Japan and India. . Hilly areas. Usually found in wet places .

Description:
Perennial growing to 0.6m.
It is hardy to zone 0. The flowers are hermaphrodite (have both male and female organs)

CLICK & SEE THE PICTURES
The plant prefers light (sandy), medium (loamy) and heavy (clay) soils. The plant prefers acid, neutral and basic (alkaline) soils. It can grow in semi-shade (light woodland) or no shade. It requires moist soil.

Cultivation :
This plant was formerly cultivated on quite a large scale as a dye plant in China and India, but has now been superseded by artificial dyes and is only grown on a small scale . A monocarpic plant, living for a number of years without flowering but then dying after flowering.

Propagation:

Through Seeds

Medicinal Uses:
Depurative; Febrifuge.
The roots and leaves are depurative and febrifuge. A decoction is used in the treatment of epidemic mumps, sore throat, erysipelas and fever-caused rashes.

Natural Indigo is the dried powder or mass prepared from the leaf or the stem and leaf of Baphicacanthus cusia (Ness) Bremek. (Fam. Acanthaceae),polygonum thinctorium Ait. (Fam. polygonaceae) or Isatis indigotica Fort. (Fam. Cruciferae).

Action:
To remove toxic heat, to reduce heat in blood , and to relieve convulsions.


Indications:
Eruptive epidemic diseases; spitting of blood and epistaxis due to heat in the blood chest pain and hemoptysis; ulcers in the mouth; mumps; pharyngitis, karyngitis; infantile convulsion.

Usage:
Used for making pills or powder, appropriate quantity for external use.
Other Uses:-.….>.
Dye.
An indigo blue dye is obtained from the leaves.....CLICK & SEE.

Disclaimer:The information presented herein is intended for educational purposes only. Individual results may vary, and before using any supplements, it is always advisable to consult with your own health care provider.

Resources:
http://www.pfaf.org/database/plants.php?Baphicacanthus+cusia
http://www.fzrm.com/plantextracts/Natural_Indigo_extract.htm

Reblog this post [with Zemanta]
Categories
Herbs & Plants

Camel Thorn(Alhagi maurorum)

[amazon_link asins=’3848418916,3659270334′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’972bbb39-0f82-11e7-a627-6d5c3321d316′]

[amazon_link asins=’1945568038,1453856641′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’f62f9cb4-0f82-11e7-aa36-639dc9d2d5c0′]

Botanical Name :Alhagi maurorum
Family: Fabaceae/Leguminosae
Subfamily: Faboideae
Kingdom: Plantae
Division: Magnoliophyta
Class: Magnoliopsida
Order: Fabales
Genus: Alhagi
Species: A. maurorum
SynonymsAlhagi camelorum – Fisch.,Alhagi persarum – Boiss.&Buhse., Alhagi pseudalhagi – (M.Bieb.)Desv. ex B.Keller.&Shap., Hedysarum pseudalhagi – M.Bieb.
Common Name : Camelthorn. Manna tree,

Habitat: This shrub is native to the region extending from the Mediterranean to Russia but has been introduced to many other areas of the world, including Australia, southern Africa, and the western United States.   Edges of ditches, waste and often saline places etc in Turkey. Grows in dry barren places.

Description:
The decidious perennial plant grows from a massive rhizome system which may extend over six feet deep into the ground. New shoots can appear over 20 feet from the parent plant. Above the ground the plant rarely reaches four feet in height. It is a heavily-branched gray-green thicket with long spines along the branches. It bears small bright pink to maroon pea flowers and small legume pods which are brown or reddish and constricted between the seeds. The seeds are mottled brown beans.
..CLICK & SEE
The plant, which is grayish green and hairless, has simple, entire leaves that are alternately arranged. The leaf shape is oval to lance-shaped. The small (3/8 inch), pea-like flowers are pinkish purple to maroon and are borne on short, spine-tipped branches that arise from the leaf axils. The reddish-brown to tan fruits are constricted between the seeds, with a short narrow beak at the end.

Camelthorn is a noxious weed in its non-native range. It is a contaminant of alfalfa seed and grows readily when accidentally introduced to a cultivated field. It has a wide tolerance of soils, thriving on saline, sandy, rocky, and dry soils. It does best when growing next to a source of water, such as an irrigation ditch. It is unpalatable to animals and irritating when it invades forage and grazing land.

It is hardy to zone 0. It is in flower in July. The flowers are hermaphrodite (have both male and female organs)It can fix Nitrogen.
The plant prefers light (sandy) and medium (loamy) soils and requires well-drained soil. The plant prefers acid, neutral and basic (alkaline) soils and can grow in saline soil. It cannot grow in the shade. It requires dry or moist soil.

Cultivation :
Requires a sunny position in a well-drained light or medium soil. Plants are not very hardy in Britain, they can be grown outdoors in the summer but require protection in the winter. The stems of the plant are covered in sharp spines. Like the closely related gorse (Ulex europaea) the flowers have a pineapple scent. (A slightly strange report because the gorse flowers have a strong coconut fragrance.) This species has a symbiotic relationship with certain soil bacteria, these bacteria form nodules on the roots and fix atmospheric nitrogen. Some of this nitrogen is utilized by the growing plant but some can also be used by other plants growing nearby.

Propagation
:-
Seed – pre-soak the seed for 12 hours in warm water and sow March/April in a warm greenhouse. When large enough to handle, prick the seedlings out into individual pots and grow them on in a greenhouse for at least the first winter. Plant out into their permanent positions in the summer. Cuttings of young shoots in a frame.

Edible Uses:-
Edible Parts: Manna.

A sweet-tasting manna is exuded from the twigs at flowering time. It is exuded during hot weather according to one report. It contains about 47% melizitose, 26% sucrose, 12% invert sugar. Another manna is obtained from the pods – it is sweet and laxative. Root – cooked. A famine food, it is only used in times of need .

Medicinal Actions &  Uses
:-
Diaphoretic; Diuretic; Expectorant; Laxative.

The whole plant is diaphoretic, diuretic, expectorant and laxative. An oil from the leaves is used in the treatment of rheumatism. The flowers are used in the treatment of piles.


Scented Plants

Flowers: Fresh
The flowers have a pineapple scent.

Resources:
http://www.pfaf.org/database/plants.php?Alhagi+maurorum
http://www.wildflowers.co.il/english/plant.asp?ID=183
http://en.wikipedia.org/wiki/Alhagi_maurorum

http://www.texasinvasives.org/invasives_database/detail.php?symbol=ALMA12

Reblog this post [with Zemanta]
Categories
News on Health & Science

Mammogram Guidelines: What You Need to Know

[amazon_link asins=’016045316X’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’f9eac28d-c510-11e7-a149-d1e58b17a042′]

[amazon_link asins=’1619845385,B076J9QJKX,B00EJWYG7S,B01M3SD8P7,B075X3KRFF,B01M0AG01N’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’13fbbbb6-c511-11e7-a573-6ba8d0df0a12′]

If the brouhaha following a government advisory panel’s recent change in breast-cancer-screening recommendations has proved anything, it is that even modern medicine does not rely on statistics, scientific facts and clinical outcomes alone.

CLICK & SEE

That’s the hard lesson that the U.S. Preventive Services Task Force (USPSTF) learned when it changed course on its recommendations for mammography screening and advised women to delay having the screen until they are 50, rather than beginning evaluations at 40, as they have recommended previously. Over the past two decades, annual mammograms for women over 40 had become a standard of preventive care in the U.S. — right up there with daily exercise, quitting smoking and getting a flu shot.
(Read “Understanding the Health-Care Debate: Your Indispensable Guide”)

But after taking a more in-depth look at the numbers, the task force decided that the risks of mammography for women in their 40s do not outweigh the small benefit that the screens provide. On top of that, the panel recommended that doctors no longer urge women to perform monthly breast self-exams at home, citing a lack of scientific evidence to support that they save lives.

Immediately, almost every major cancer organization and physicians’ group — including the American Cancer Society, the Susan G. Komen Breast Cancer Foundation and the American College of Ostetricians and Gynecologists — questioned the new recommendations. So did women. “I’m just shocked, absolutely shocked,” says Deana Rich, a clinical-research associate in Seattle. The 47-year-old has no family history of breast cancer but has been dutifully getting an annual mammogram for the past seven years in order to reduce her risk of dying from the disease. One of her friends recently received a breast-cancer diagnosis, and several other friends are breast-cancer survivors; all of them learned of their disease thanks to a routine mammogram they got during their 40s. “I can’t imagine what would have happened if they didn’t have that. The cancer would have just had more time to grow,” says Rich.
(See 10 players in health-care reform.)

That is the biggest worry boiling up among doctors and women across the country — that a procedure that undeniably reduces the risk of breast cancer is no longer being recommended for millions of women. Another worry: will insurance begin denying coverage of breast-cancer screens in women under 50 who want them? The Obama Administration quickly disputed that notion, as well as the suggestion that the panel’s advisory was a government strategy to cut costs by rationing health care. “The U.S. Preventive Task Force is an outside, independent panel of doctors and scientists who make recommendations,” said Secretary of Health and Human Services Kathleen Sebelius in a statement. “They do not set federal policy, and they don’t determine what services are covered by the Federal Government.”

Sebelius added that private insurance companies were unlikely to change their policies and that mammograms are a valuable lifesaving tool. She advised women to “keep doing what you have been doing for years. Talk to your doctor about your individual history, ask questions and make the decision that is right for you.”

Indeed, the mammogram is one of doctors’ most powerful tools against breast cancer. There is a robust body of clinical-trial evidence showing that routine screening reduces breast-cancer deaths; the task force attests to that as well. But while everybody, to varying extent, agrees that mammograms are beneficial, what’s less clear is the age at which routine mammography screening should begin. That depends in part on breast cancer risk, which increases with age — for every 100,000 women, the risk of developing breast cancer is 1 in 69 in women in their 40s, 1 in 38 in women in their 50s, and 1 in 27 among women in their 60s.

Consensus on this question would be helpful because professional cancer organizations, cancer hospitals and doctors base their screening guidelines on the advice of nationally recognized groups — like the American Cancer Society and the National Comprehensive Cancer Network (or NCCN, a coalition of National Cancer Institute–designated hospitals), and the USPSTF. Neither the ACS nor the NCCN intends to modify its guidelines for yearly breast-cancer screening in all healthy women over 40.

So how exhaustive was the task force’s deliberation? How definitive are its guidelines? And which set of recommendations should women follow?

The USPSTF, a volunteer group of 16 health professionals, is often considered to issue the most conservative recommendations compared with other national groups. In 2002, for instance, it called for breast-cancer screening every one or two years for women ages 40 to 49, while other guidelines advocated yearly tests. For its updated 2009 recommendations, the USPSTF analyzed clinical trials on the benefits of mammography — much of that same research was also evaluated for the task force’s 2002 decision — while folding in new data on the risks and harms of screening. Those risks include false positive results, over-diagnosis, patient anxiety and unnecessary biopsies, tests and doctor’s visits.

The panel also commissioned computer-modeling studies that weighed the benefits of routine screening (reduction in death rate) against its risks, depending on the ages of the women being screened and how often they were tested — every year or every other year.

Overall, based on a review of mammography trials, the panel found that having a yearly mammogram screening cuts the risk of breast-cancer death 15% in women ages 40 to 49. That reduction, it should be noted, is relative, not absolute. The absolute risk of breast-cancer death after age 40 is 3% without annual screening, according to the computer models. That means that with routine screening, which leads to a 15% lower risk of death from breast cancer, a woman’s absolute risk drops to 2.6%. Small numbers in either case. Put another way, the panel concluded, the benefit of routine mammograms for women in their 40s is one fewer death for every 1,904 women screened annually for up to a decade.

That benefit increases, however, with the age of the women being screened, as the risk of breast cancer rises: among women 50 to 59, one death is averted for every 1,339 women routinely screened; among women 60 to 69, 377 mammograms would be needed to prevent one death. The task force’s computer models further showed that shifting women’s screening schedule from yearly to once every two years retains 81% of the benefit of screening while reducing the harms like false positives by half.

Combined, the findings led the panel to reverse their 2002 recommendations on mammography, which extended the advice, originally targeting women over 50, to also include women in their 40s. The new recommendations, published in the Nov. 17 issue of the Annals of Internal Medicine, once again leave out the younger women and suggest that those over 50 get screened biennially. But the recommendations do not instruct women under 50 never to get screened, says Dr. Diana Petitti, vice chair of the task force. The new guidelines were meant to trigger and inform discussion between women in their 40s and their doctors about routine screening. “We thought we were saying that the evidence shows that there is this amount of benefit and this amount of potential harm for women in their 40s,” she says. “Which suggests that routine screening is not appropriate. But the word routine clearly got lost.”

Such details were bound to get lost in a heated — and highly politicized — discussion of a topic that is for most women more emotional than medical. Add to that an immediate offensive blitz by some cancer doctors who were concerned that the new guidelines would essentially limit their patients’ options for preventing breast-cancer death. “I am appalled and horrified,” says Dr. David Dershaw, director of breast imaging at Memorial Sloan-Kettering Cancer Center. “We have something that saves lives, and to say we are not going to do it anymore is unconscionable.”

The panel stands by its new recommendations, relying on the data, which simply do not support the benefit of routine screening when balanced with risks, among younger women. The new recommendations are also backed by some prominent physicians, including the cancer surgeon Dr. Susan Love, who agree there’s insufficient data to show that screening under 50 works. The debate, says Dr. Len Lichtenfeld of ACS, is not likely to end soon. “This is the beginning of a discussion that will likely continue vigorously over the next several months, if not years,” he predicts.

But the more immediate issue for many cancer doctors is not that mammograms may work better in some age groups than in others. What worries experts is that the new guidelines could result in fewer women getting screened overall. Already one-third of American women who should be getting annual mammograms do not get screened. Since 1990, the death rate from breast cancer among women under 50 has been declining, 3% each year, in large part because of the expanded screening guidelines. “[The new recommendations] may erode some of the advances we had made in reducing breast-cancer mortality,” says Dr. Therese Bevers, a professor of clinical cancer prevention at M.D. Anderson Cancer Center in Houston.

For Deana Rich’s part, she plans to continue with her annual screenings, even if at some point she ends up paying for them herself. “It’s just too scary not to get mammograms,” she says. “I know it’s not the be all and end all, but it is one screening tool that we do have.”

Source:Health & Science. 20th. Nov. ’09

Reblog this post [with Zemanta]
css.php